Literature DB >> 1149778

Hepatic cholesterol synthesis in man: effect of diazepam and other drugs.

F Orlandi, F Bamonti, M Dini, M Koch, A M Jezequel.   

Abstract

The hepatic synthesis of cholesterol-measured as incorporation of 14C-acetate into digitonin-precipitable sterols-has been evaluated in needle biopsy material of normal untreated patients and patients under short-term treatment with Diazepam, Phenobarbital, Chlorpromazine or Diphenylhydantoin. A significant increase of cholesterol synthesis was observed in the first two groups with much higher levels of incorporation in the Diazepam-treated patients. Moreover in this group the levels were still elevated from 4 to 7 days after drug withdrawl. Ultrastructural and morphometric studies performed on the same biopsy material showed a significant increase of smooth endoplasmic reticulum in hepatocytes of Diazepam-treated patients; in addition, there seemed to be a positive correlation between the increased cholesterol synthesis and the formation of areas of non vesicular, type 2, smooth endoplasmic reticulum. These findings suggest an early stimulation of the liver cell microsomal system by Diazepam in man; they also point to side effects of some drugs, which are not predictable from studies in Wistar rats.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149778     DOI: 10.1111/j.1365-2362.1975.tb00439.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  [Postmortem evaluation of barbiturate poisonings].

Authors:  A Schmoldt; E R Beckmann; W Horstmann
Journal:  Z Rechtsmed       Date:  1984

2.  Evidence that chlorpromazine inhibits sterologenesis at post-HMGCoA reductase sites in rat liver, in vitro.

Authors:  F P Bell; E V Hubert
Journal:  Lipids       Date:  1983-09       Impact factor: 1.880

3.  Inhibition of acyl CoA: cholesterol acyltransferase and sterologenesis in rat liver by diazepam, in vitro.

Authors:  F P Bell
Journal:  Lipids       Date:  1985-02       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.